Literature DB >> 33543400

Combining targeted sequencing and ultra-low-pass whole-genome sequencing for accurate somatic copy number alteration detection.

Junfeng Fu1, Weihua Guo2, Cheng Yan2, Zhenyang Lv1, Yu Wang1, Ze Wang1, Zhe Fan1, Ting Lei3.   

Abstract

This study investigated the feasibility of combining targeted sequencing and ultra-low-pass whole-genome sequencing (ULP-WGS) for improved somatic copy number alteration (SCNA) detection, due to its role in tumorigenesis and prognosis. Cerebrospinal fluid and matched blood samples were obtained from 29 patients with brain metastasis derived from lung cancer. Samples were subjected to targeted sequencing (genomic coverage: 300 kb) and 2×ULP-WGS. The SCNA was detected by the CTLW_CNV, Control-FreeC, and CNVkit methods and their accuracy was analyzed. Eighteen tumor samples showed consistent SCNA results between the three methods, while a small fraction of samples resulted in different SCNA estimations. Further analysis indicated that consistency of SCNA highly correlated with the difference of baseline depth (normalized depth of regions without SCNA events) estimation between methods. Conflict Index showed that CTLW_CNV significantly improved the accuracy of SCNA detection through precise baseline depth estimation. CTLW_CNV combines targeted sequencing and ULP-WGS for improved SCNA detection. The improvement in detection accuracy is mainly due to a refined baseline depth estimation, guided by single-nucleotide polymorphism allele frequencies within the deeply sequenced region (targeted sequencing). This method is especially suitable for tumor samples with biased aneuploidy, a previously under-estimated genomic characteristic across different cancer types.

Entities:  

Keywords:  SCNV baseline; Somatic copy number alteration; Targeted sequencing; Ultra-low-pass whole-genome sequencing; WGD

Year:  2021        PMID: 33543400     DOI: 10.1007/s10142-021-00767-y

Source DB:  PubMed          Journal:  Funct Integr Genomics        ISSN: 1438-793X            Impact factor:   3.410


  2 in total

1.  Genome-Informed Targeted Therapy for Osteosarcoma.

Authors:  Leanne C Sayles; Marcus R Breese; Amanda L Koehne; Stanley G Leung; Alex G Lee; Heng-Yi Liu; Aviv Spillinger; Avanthi T Shah; Bogdan Tanasa; Krystal Straessler; Florette K Hazard; Sheri L Spunt; Neyssa Marina; Grace E Kim; Soo-Jin Cho; Raffi S Avedian; David G Mohler; Mi-Ok Kim; Steven G DuBois; Douglas S Hawkins; E Alejandro Sweet-Cordero
Journal:  Cancer Discov       Date:  2018-09-28       Impact factor: 39.397

2.  Somatic copy number alterations have prognostic impact in patients with ovarian clear cell carcinoma.

Authors:  Asuka Morikawa; Tomoatsu Hayashi; Mana Kobayashi; Yuki Kato; Katsuhiko Shirahige; Takehiko Itoh; Mitsuyoshi Urashima; Aikou Okamoto; Tetsu Akiyama
Journal:  Oncol Rep       Date:  2018-05-08       Impact factor: 3.906

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.